Mesh Bio Secures $3.5M Series A Funding for Digital Twin Technology Expansion in Healthcare

Mesh Bio rses $3.5 million in Series A funding from leading Southeast Asia-focused venture capital firm East Ventures to accelerate digital twin technology adoption across healthcare

Singapore-based health deep tech startup, Mesh Bio, is making strides toward transforming the management of chronic diseases through advanced predictive analytics with its recent announcement of rsing $3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focused on Southeast Asia. Elev8, Seed Capitals, and other existing investors also participated in this round.

The investment will facilitate Mesh Bio's expansion plans for its digital twin technologies, enabling their scaled deployment across healthcare providers in Hong Kong and the Southeast Asian region, particularly in Indonesia and the Philippines.

Mesh Bio has recently achieved a significant milestone with regulatory approval from Singapore’s Health Sciences Authority HSA to market its HealthVector Diabetes as a Software Medical Device SaMD. This approval opened up an opportunity for improved patient outcomes through chronic disease management, as the technology is currently being piloted at several healthcare facilities including Singapore General Hospital, Tan Tock Seng Hospital, and selected polyclinics.

Dr. Andrew Wu, Co-Founder and CEO of Mesh Bio, expressed excitement about this development:

We are thrilled to announce our Series A funding milestone which marks a crucial step in scaling our digital health solutions for chronic disease management across Southeast Asia.”

The high prevalence of chronic diseases such as diabetes and heart disease presents an immense challenge to healthcare systems in the region where many primary care physicians lack specialized trning. Mesh Bio address this gap through its cutting-edge technologies, offering healthcare providers access to patient data and predictive analytics that enhance decision-making.

Mesh Bio's DARA Health Intelligence Platform already supports preventive health screening across more than 120 medical centers in Singapore, Malaysia, and Indonesia. The company has since expanded the platform into chronic disease management with the introduction of HealthVector Diabetes.

We are grateful for East Ventures' ongoing support, sd Dr. Wu. We see Southeast Asia as a hub for innovation to tackle healthcare challenges that require personalized and preventive care services. We look forward to collaborating further in revolutionizing healthcare systems across this region.

Mesh Bio was co-founded by Andrew Wu CEO and Arsen Batagov CTO, with previous investments including a $1.8 million seed funding round conducted in October 2021.

For the complete reference of all East Ventures' funded companies, visit:https:www.eastventures.comfirms

of Document
This article is reproduced from: https://east.vc/news/press-release/mesh-bio-raises-series-a-funding-led-by-east-ventures/

Please indicate when reprinting from: https://www.ci56.com/Financing_investment/Mesh_Bio_Series_A_Funding.html